Request Demo
Last update 11 Apr 2026
BL-M05D1
Last update 11 Apr 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms BL-M05D1 |
Target |
Action inhibitors |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
3
Clinical Trials associated with BL-M05D1NCT07518147
A Randomized Controlled Phase III Clinical Study Comparing BL-M05D1 for Injection With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) 18.2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-line Treatment
NCT07021066
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors
NCT06349811
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with BL-M05D1
Login to view more data
100 Translational Medicine associated with BL-M05D1
Login to view more data
100 Patents (Medical) associated with BL-M05D1
Login to view more data
100 Deals associated with BL-M05D1
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced gastric carcinoma | Phase 3 | China | 01 Apr 2026 | |
| CLDN18.2 positive Stomach Cancer | Phase 3 | China | 01 Apr 2026 | |
| Locally Advanced Gastroesophageal Junction Adenocarcinoma | Phase 3 | China | 01 Apr 2026 | |
| Adenocarcinoma of Esophagus | Phase 1 | United States | 30 Jul 2025 | |
| Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 30 Jul 2025 | |
| Biliary Tract Neoplasms | Phase 1 | United States | 30 Jul 2025 | |
| Metastatic Solid Tumor | Phase 1 | United States | 30 Jul 2025 | |
| stomach adenocarcinoma | Phase 1 | United States | 30 Jul 2025 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 19 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free